Humacyte (HUMA) Cash from Operations (2020 - 2026)
Humacyte (HUMA) posted quarterly Cash from Operations of 25100000.0 for Q1 2026, up 12.24% year-over-year from 22363239.88 in Q1 2025, and up 3.77% quarter-over-quarter from 26082000.0 in Q4 2025.
Humacyte (HUMA) Cash from Operations (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Cash from Operations for 7 consecutive years, with 25100000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 12.24% year-over-year to 25100000.0; the TTM figure through Mar 2026 stood at 101500000.0 (down 2.16% YoY), while the FY2025 annual figure was 105000000.0, down 7.03% from the prior year.
- Cash from Operations advanced to 25100000.0 in Q1 2026 per HUMA's latest filing, from 26082000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 13007000.0 in Q3 2023 and bottomed at 28600000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 21917647.06 across 5 years, with a median of 22603000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 44.97% — and 2024, when it slumped 76.11%.
- Humacyte's Cash from Operations stood at 18930000.0 in 2022, then retreated by 0.63% to 19049000.0 in 2023, then sank by 39.4% to 26555000.0 in 2024, then increased by 1.78% to 26082000.0 in 2025, then climbed by 3.77% to 25100000.0 in 2026.
- Business Quant data shows HUMA's Cash from Operations at 25100000.0 in Q1 2026, 26082000.0 in Q4 2025, and 23904000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -22.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.10 Mn |
| Jun 30, 2026 | -22.10 Mn |
| Mar 31, 2026 | -25.10 Mn |
| Mar 31, 2026 | -25.10 Mn |
| Dec 31, 2025 | -26.08 Mn |
| Dec 31, 2025 | -26.08 Mn |
| Sep 30, 2025 | -23.90 Mn |
| Sep 30, 2025 | -23.90 Mn |
| Jun 30, 2025 | -26.41 Mn |
| Jun 30, 2025 | -26.41 Mn |
| Mar 31, 2025 | -28.60 Mn |
| Mar 31, 2025 | -28.60 Mn |
| Dec 31, 2024 | -26.56 Mn |
| Dec 31, 2024 | -26.56 Mn |
| Sep 30, 2024 | -22.91 Mn |
| Sep 30, 2024 | -22.91 Mn |
| Jun 30, 2024 | -21.29 Mn |
| Jun 30, 2024 | -21.29 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Mar 31, 2024 | -27.35 Mn |